Minimizing the immunogenicity of protein therapeutics (Q35687687)

9 August 2017

1 reference

title

Minimizing the immunogenicity of protein therapeutics (English)

1 reference

9 August 2017

Arthur J Chirino

1

1 reference

9 August 2017

Marie L Ary

series ordinal

2

1 reference

9 August 2017

Shannon A Marshall

series ordinal

3

1 reference

9 August 2017

language of work or name

1 reference

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

9

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

82-90

1 reference

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Immunogenicity of therapeutic proteins: clinical implications and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Role of aggregated human growth hormone (hGH) in development of antibodies to hGH

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Capacity of antigen uptake by B cells, fibroblasts or macrophages determines efficiency of presentation of a soluble self antigen (C5) to T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

In vivo induction of CD4+ T cell responses by antigens covalently linked to synthetic microspheres does not require adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Helper T-cell-regulated B-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Nomenclature for factors of the HLA system, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Infectious Diseases and Immunity: Special Reference to Major Histocompatibility Complex

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

The role of the major histocompatibility complex in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Identification of an association between HLA class II alleles and low antibody levels after measles immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

In vitro priming of human lymphocytes to heterologous insulins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Immunogenicity of biopharmaceuticals in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Convergent evolution of major histocompatibility complex molecules in humans and New World monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Unprecedented polymorphism of Mhc-DRB region configurations in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Birth of MHC-defined rhesus monkeys produced by assisted reproductive technology

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

HLA class II transgenic mice: models of the human CD4+ T-cell immune response.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Quantitative analysis of peptide-MHC class II interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Human immune response to recombinant human proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Rational design and engineering of therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Detection of peptide-MHC class II complexes on the surface of intact cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Computational stabilization of human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902953-2

7 January 2021

10.1016/S1359-6446(03)02953-2

Identifiers

DOI

1 reference

release_5dxiuxd7vza3xcaqvcvesmudwu

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5dxiuxd7vza3xcaqvcvesmudwu

24 November 2022

mapped directly with Wikidata item

1 reference